<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 17, 2026 at 6:39 am by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Tue, 17 Nov 2026 04:41:25 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://www.pharmavoice.com/news/china-pharma-global-expansion-us-commercialization/874673/]]></guid>
			<link><![CDATA[https://www.pharmavoice.com/news/china-pharma-global-expansion-us-commercialization/874673/]]></link>
			<title>China’s pharma industry wants to go global. The US could get in its way.</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 04:41:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/]]></link>
			<title>One of Europe’s leading VCs banks a €725M ‘crossover’ fund</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:07:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/]]></link>
			<title>Big-name investors pour $100M into DNA therapeutics developer Seawolf</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:07:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/spons/the-infrastructure-decisions-that-will-enable-tomorrows-biggest-breakthrou/874507/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/spons/the-infrastructure-decisions-that-will-enable-tomorrows-biggest-breakthrou/874507/]]></link>
			<title>The infrastructure decisions that will enable tomorrow’s biggest breakthroughs</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/]]></link>
			<title>Lilly adds to buyout streak with $1.5B purchase of startup Calytrix</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/Johnson-johnson-ollin-acquire-ophthalmology-vegf-ang2-drugs/874728/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/Johnson-johnson-ollin-acquire-ophthalmology-vegf-ang2-drugs/874728/]]></link>
			<title>J&amp;J bets $2.2B on Ollin’s vision loss drug</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/summit-akeso-fda-ivonescimab-reject-egfr-lung-cancer/874745/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/summit-akeso-fda-ivonescimab-reject-egfr-lung-cancer/874745/]]></link>
			<title>Summit shares fall as FDA rejects closely watched PD-1/VEGF drug</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:06:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/biospace-40-under-40-winners-paull-zhang-let-patients-with-rare-disease-lead-the-way-at-bridgebio]]></guid>
			<link><![CDATA[https://www.biospace.com/business/biospace-40-under-40-winners-paull-zhang-let-patients-with-rare-disease-lead-the-way-at-bridgebio]]></link>
			<title>BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/opinion-emerging-biotech-hubs-step-up-as-innovation-economics-evolve]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/opinion-emerging-biotech-hubs-step-up-as-innovation-economics-evolve]]></link>
			<title>Emerging biotech hubs step up as innovation economics evolve</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/their-loss-our-gain-canada-makes-its-case-to-europe-amid-u-s-instability]]></guid>
			<link><![CDATA[https://www.biospace.com/business/their-loss-our-gain-canada-makes-its-case-to-europe-amid-u-s-instability]]></link>
			<title>Their loss, our gain? Canada makes its case to Europe amid U.S. instability</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/novos-cagrisema-drives-more-than-20-weight-loss-at-lower-doses]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/novos-cagrisema-drives-more-than-20-weight-loss-at-lower-doses]]></link>
			<title>Novo’s CagriSema drives more than 20% weight loss at lower doses</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/fdas-summit-rejection-puts-pd-1xvegf-class-on-notice-to-establish-overall-survival]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/fdas-summit-rejection-puts-pd-1xvegf-class-on-notice-to-establish-overall-survival]]></link>
			<title>FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/deals/j-j-pays-2-2b-upfront-for-ollin-taps-blackstone-to-fund-eye-disease-trial]]></guid>
			<link><![CDATA[https://www.biospace.com/deals/j-j-pays-2-2b-upfront-for-ollin-taps-blackstone-to-fund-eye-disease-trial]]></link>
			<title>J&amp;J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></link>
			<title>Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/serious-adverse-events-mar-robust-efficacy-data-for-helus-psychedelic-in-major-depression]]></link>
			<title>Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 00:12:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss]]></link>
			<title>STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:48:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/beone-hengrui-top-list-of-chinas-most-powerful-drugmakers/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/beone-hengrui-top-list-of-chinas-most-powerful-drugmakers/?utm_campaign=rss]]></link>
			<title>BeOne, Hengrui top list of China’s most powerful drugmakers</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss]]></link>
			<title>STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/?utm_campaign=rss]]></link>
			<title>STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss]]></link>
			<title>STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:47:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return-on-investment/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return-on-investment/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:37:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/biotech-news-rebound-isnt-lifting-all-boats-equally/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/biotech-news-rebound-isnt-lifting-all-boats-equally/?utm_campaign=rss]]></link>
			<title>STAT+: Biotech’s rebound isn’t lifting all boats equally</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:37:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/?utm_campaign=rss]]></link>
			<title>STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:37:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss]]></link>
			<title>STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 21:37:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/low-decisional-conflict-among-prostate-cancer-patients-seeking-germline-testing/]]></guid>
			<link><![CDATA[https://bioengineer.org/low-decisional-conflict-among-prostate-cancer-patients-seeking-germline-testing/]]></link>
			<title>Low Decisional Conflict Among Prostate Cancer Patients Seeking Germline Testing</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:25:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/new-chemotherapy-quality-of-life-scale-validated-for-breast-cancer-patients/]]></guid>
			<link><![CDATA[https://bioengineer.org/new-chemotherapy-quality-of-life-scale-validated-for-breast-cancer-patients/]]></link>
			<title>New Chemotherapy Quality of Life Scale Validated for Breast Cancer Patients</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:24:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/review-evaluates-integrin-alpha-9-beta-1-potential-in-cancer-theranostics-and-preclinical-limits/]]></guid>
			<link><![CDATA[https://bioengineer.org/review-evaluates-integrin-alpha-9-beta-1-potential-in-cancer-theranostics-and-preclinical-limits/]]></link>
			<title>Review Evaluates Integrin Alpha-9-Beta-1 Potential in Cancer Theranostics and Preclinical Limits</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:24:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/mendelian-randomization-study-links-specific-viral-antibodies-to-prostate-cancer-risk/]]></guid>
			<link><![CDATA[https://bioengineer.org/mendelian-randomization-study-links-specific-viral-antibodies-to-prostate-cancer-risk/]]></link>
			<title>Mendelian Randomization Study Links Specific Viral Antibodies to Prostate Cancer Risk</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:23:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/continuous-pediatric-antibiotic-infusions-reduce-preparation-time-without-altering-perceived-workload/]]></guid>
			<link><![CDATA[https://bioengineer.org/continuous-pediatric-antibiotic-infusions-reduce-preparation-time-without-altering-perceived-workload/]]></link>
			<title>Continuous Pediatric Antibiotic Infusions Reduce Preparation Time Without Altering Perceived Workload</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:23:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/china-overtakes-europe-healthcare-investing-sentiment]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/china-overtakes-europe-healthcare-investing-sentiment]]></link>
			<title>China overtakes Europe in healthcare investing sentiment</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/azs-alexion-extends-gmg-options-two-klygefa-approvals]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/azs-alexion-extends-gmg-options-two-klygefa-approvals]]></link>
			<title>AZ&#8217;s Alexion extends gMG options with two Klygefa approvals</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/gazyva-first-fda-cleared-drug-rare-disease-pmn]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/gazyva-first-fda-cleared-drug-rare-disease-pmn]]></link>
			<title>Gazyva is first FDA-cleared drug for rare disease pMN</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/lilly-strikes-again-buying-calytrix-15bn-deal]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/lilly-strikes-again-buying-calytrix-15bn-deal]]></link>
			<title>Lilly strikes again, buying Calytrix in $1.5bn deal</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/jj-cuts-33bn-deal-buy-eye-drug-developer-ollin]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/jj-cuts-33bn-deal-buy-eye-drug-developer-ollin]]></link>
			<title>J&amp;J cuts $3.3bn deal to buy eye drug developer Ollin</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></guid>
			<link><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></link>
			<title>AstraZeneca, Calidi, Tempest make significant workforce cuts</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:05:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/novo-s-investigational-cagrisema-glp-1-amylin-analog-demonstrated-21-average-weight-loss-lower-22684.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/novo-s-investigational-cagrisema-glp-1-amylin-analog-demonstrated-21-average-weight-loss-lower-22684.html]]></link>
			<title>Novo&#8217;s Investigational CagriSema, a GLP-1 and Amylin Analog, Demonstrated ~21% Average Weight Loss with Lower Doses in the REDEFINE 9 Trial</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 17:47:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/pots-phase-2-trial-shows-baloncibart-first-class-npr1-blocking-antibody-reduced-orthostatic-heart-22683.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/pots-phase-2-trial-shows-baloncibart-first-class-npr1-blocking-antibody-reduced-orthostatic-heart-22683.html]]></link>
			<title>POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 17:47:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/s41587-026-03344-5]]></guid>
			<link><![CDATA[https://www.nature.com/articles/s41587-026-03344-5]]></link>
			<title>A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 16:24:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://phys.org/news/2026-11-tool-tracks-unintended-crispr-effects.html]]></guid>
			<link><![CDATA[https://phys.org/news/2026-11-tool-tracks-unintended-crispr-effects.html]]></link>
			<title>New tool tracks unintended CRISPR edits and their effects in individual cells</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 15:52:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/]]></link>
			<title>StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 06:51:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/summits-pd-1xvegf-rejected-by-fda-in-lung-cancer]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/summits-pd-1xvegf-rejected-by-fda-in-lung-cancer]]></link>
			<title>Summit&#8217;s PD-1xVEGF rejected by FDA in lung cancer</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 22:14:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/brodalumab-treatment-for-palmoplantar-pustulosis-linked-to-rare-pyoderma-gangrenosum-cases/]]></guid>
			<link><![CDATA[https://bioengineer.org/brodalumab-treatment-for-palmoplantar-pustulosis-linked-to-rare-pyoderma-gangrenosum-cases/]]></link>
			<title>Brodalumab Treatment for Palmoplantar Pustulosis Linked to Rare Pyoderma Gangrenosum Cases</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 18:13:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/low-palladium-zinc-oxide-boosts-antibiotic-removal-without-adding-water-toxicity/]]></guid>
			<link><![CDATA[https://bioengineer.org/low-palladium-zinc-oxide-boosts-antibiotic-removal-without-adding-water-toxicity/]]></link>
			<title>Low Palladium Zinc Oxide Boosts Antibiotic Removal Without Adding Water Toxicity</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 18:12:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/in-depth/bio-europe-2026/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/in-depth/bio-europe-2026/]]></link>
			<title>Key takeaways from BIO-Europe 2026: European biotech has the science – but does it have the backing?</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 11:43:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/industry/generic-drug-user-fee-amendments/activities-report-generic-drug-program-fdara-title-viii-sections-807-and-805]]></guid>
			<link><![CDATA[http://www.fda.gov/industry/generic-drug-user-fee-amendments/activities-report-generic-drug-program-fdara-title-viii-sections-807-and-805]]></link>
			<title>Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 09:19:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/]]></link>
			<title>How Vancomycin-Resistant Enterococcus Evolved in a Danish Hospital</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 22:13:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/arrowheads-ionis-problem-kyvernas-next-gen-end-and-more-biotech-earnings]]></guid>
			<link><![CDATA[https://www.biospace.com/business/arrowheads-ionis-problem-kyvernas-next-gen-end-and-more-biotech-earnings]]></link>
			<title>Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 16:36:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-delivery/pharmalogic-buys-lantheus-plant-to-build-transatlantic-radiopharmaceutical-cdmo]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-delivery/pharmalogic-buys-lantheus-plant-to-build-transatlantic-radiopharmaceutical-cdmo]]></link>
			<title>PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 16:36:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies]]></link>
			<title>Cellectis could cut 70% of workforce in shift to in vivo therapies</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 16:36:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
